 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"New drugs for 'Prediabetes', Metabolic Syndrome and their CVD consequences: GLP-1"Prof. Michael A. Nauck (biography)
English - 2005-04-15 - 23 minutes
|
 | (21 slides) |
Summary :
Glucagon-like Peptide 1 (GLP-1) is a gut hormone with incretin and "ileal brake" activity. There are many facets of its action that add up to antidiabetic effects: (a) glucose-dependent stimulation of insulin secretion, (b) a glucagonostatic activity, (c) a deceleration of gastric emptying, (d) a suppression of appetite (and reduction in food intake), and effects on islet B cells demonstrated in animal studies, e.g. formation, regeneration, and neogenesis of B cells and an inhibition of apoptosis induced by several B cell toxins. GLP-1 as the natural hormone has a very short half-life (< 2 min) and cannot be used for treatment of a chronic condition. Incretin mimetics like exenatide, liraglutide and other derivatives of GLP-1) have the potential to lower glucose and HbA1c in Type 2-diabetic patients. They also induce some weight loss, very much in contrast to other insulinotropic antidiabetic drugs. Since all incretin mimetics developed so far are peptides and need to be injected, they have been thought to be useful after oral antidiabetic failure. The clinical profile, however, suggests that tight glucose control together with weight loss (or at least the prevention of weight gain) could be helpful at earlier stages in the development of Type 2 diabetes, perhaps also in prediabetic stages. GLP-1 is effective in subjects with IGT. However, longer-term studies in prediabetic subjects have not been performed, but are needed before the effectiveness of incretin mimetics for the prevention of diabetes or its sequalae can be proven.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Antidiabetic effects of GLP-1
- Incretin mimetics: GLP-1 receptor antagonists with prolonged pharmacokinetic profiles
- Efficacy of GLP-1 in subjects with IGT
- Antiapoptotic effect of GLP-1
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
